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ABSTRACT 
 
 
Although the use of chemotherapy has evolved remarkably during the past 30 years for 
treatment in leukemia patients, it remains a difficult disease to treat where the main 
problem is drug resistance. This is due to over expression of multi-drug resistance gene 
(MDR1) and it’s over expression has been described in many tumors resistant to 
cytotoxic drugs including leukemias. This gene is polymorphic and studies in different 
ethnic groups have indicated that the three most frequent single nucleotide 
polymorphisms (SNPs) are located in exons 12, 21 and 26 of the MDR1 gene. Denaturing 
high performance liquid chromatography (dHPLC) has been proven to be a feasible 
method in detecting target DNA for presence of mutations and polymorphisms including 
in the MDR1 gene. Studies on polymorphisms of the MDR1 gene, however has not been 
carried out in patients in this institution. Thus, the main objectives of this study were to 
develop and establish dHPLC technique for screening of these three most frequent 
polymorphisms located in exons 12, 21 and 26 of the MDR1 gene, to investigate the 
distribution of these polymorphisms of the MDR1 gene and to compare and combine the 
results from dHPLC technique with restriction fragment length polymorphism (RFLP) in 
detection of these polymorphisms of the MDR1 gene in Malay patients with leukemia in 
this institution. A total of hundred and one DNA samples from Malay patients diagnosed 
as leukemia were studied and subjected to dHPLC analysis and RFLP analysis. Statistical 
analysis was done using chi-square (χ2) and Fisher Exact’s test. Out of these, there were 
35 (34.7%) patients diagnosed as acute myeloid leukemia (AML), 48 (47.5%) as acute 
 xxi 
lymphoblastic leukemia (ALL) and 18 (17.8%) as chronic myeloid leukemia (CML). 
There were 58 (57.4%) males and 43 (42.6%) females. From the results, if all of the three 
exons were combined, 25 (25.7%) of the patients showed heterozygous mutation, 7 
(6.7%) of them had wild type, while 2 (1.9%) showed homozygous mutation. In all of 
these patients, there was a significant difference in the distribution of polymorphisms 
between exons 21 and 26 with a p<0.05. PCR-RFLP assays had been performed to 
confirm the results of dHPLC technique and there were 93.2%, 96.1% and 100% of 
common polymorphisms detected in exons 12, 21 and 26, respectively. In this study 
dHPLC was successfully developed for detection of common polymorphisms in the 
MDR1 gene in Malay patients with leukemia in this institution. The clinical implications 
of the distribution of these polymorphisms especially in the response of treatment in these 
patients should be studied for the future.    
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PEMBANGUNAN TEKNIK KROMATOGRAFI CECAIR DENATURASI 
BERPRESTASI TINGGI (dHPLC) DALAM MENGESAN POLIMORFISME 
YANG LAZIM PADA GEN KERINTANGAN PELBAGAI DADAH (MDR1) DI 
KALANGAN PESAKIT MELAYU YANG MENGHIDAP LEUKIMIA 
 
ABSTRAK 
 
Walaupun keberkesanan penggunaan kemoterapi dalam rawatan terhadap pesakit 
leukimia adalah jelas terbukti, namun leukimia tetap merupakan penyakit yang sukar 
dirawat terutamanya dalam masalah kerintangan pesakit terhadap ubat-ubatan (dadah). 
Ini disebabkan oleh pengekspresan gen kerintangan pelbagai dadah (multidrug resistance 
gene, MDR1) yang berlebihan dan ianya telah dilaporkan dalam kebanyakan pesakit 
tumor yang rintang terhadap dadah sitotoksik termasuk leukimia. Gen ini adalah gen 
yang polimorfik dan kajian di dalam kumpulan etnik yang berlainan menunjukkan 
bahawa tiga polimorfisme nukleotida tunggal (SNPs) yang paling kerap berlaku adalah 
terletak pada ekson-ekson 12, 21 dan 26 pada gen MDR1. Teknik denaturasi cecair 
berprestasi tinggi (dHPLC) telah dibuktikan sebagai suatu teknik yang berkesan dalam 
pengesanan mutasi dan polimorfisme, begitu juga dalam gen MDR1. Kajian pengesanan 
polimorfisme pada gen MDR1 masih belum pernah dijalankan dikalangan pesakit 
leukimia di institusi ini. Oleh itu, objektif utama kajian ini adalah untuk membangunkan 
teknik dHPLC bagi menyaring ketiga-tiga ekson tersebut; ekson 12, 21 dan 26 pada gen 
MDR1, mengkaji taburan polimorfisme gen MDR1 dan seterusnya membanding serta 
 xxiii 
menggabungkan hasil di antara teknik dHPLC dan restriction fragment length 
polymorphism (RFLP) dalam mengesan polimorfisme ini dikalangan pesakit Melayu 
yang menghidap leukemia. Sebanyak 101 sampel DNA pesakit-pesakit Melayu yang 
menghidap leukimia telah digunakan dalam kajian ini. Analisa statistik telah dilakukan 
menggunakan ujian-ujian chi-square (χ2) dan Fisher Exact. Daripada keseluruhan 
sampel, sebanyak 35 (34.7%) adalah merupakan leukimia myeloid jenis akut (AML), 48 
(47.5%) merupakan leukemia lymphoblastic jenis akut (ALL) and 18 (17.8%) merupakan 
leukemia myeloid jenis kronik (CML). Sebanyak 58 (57.4%) sampel adalah merupakan 
pesakit  lelaki dan 43 (42.6%) sampel adalah perempuan terlibat di dalam kajian ini. 
Sekiranya hasil daripada ketiga-tiga ekson digabungkan, didapati 25 (25.7%) sampel 
daripada keseluruhan pesakit menunjukkan mutasi heterozigus, 7 (6.7%) sampel 
menunjukkan profil jenis liar sementara 2 (1.9%) sampel menunjukkan mutasi 
homozigus. Di kalangan pesakit-pesakit ini, terdapat perbezaan yang bererti bagi 
penyebaran polimorfisme di antara ekson 21 dan ekson 26 dengan nilai p<0.05. Teknik 
PCR-RFLP telah dijalankan bagi mengesahkan profil yang telah ditemui oleh teknik 
dHPLC dan sebanyak 93.2%, 96.1% and 100% polimorfisme yang lazim telah 
dikenalpasti hadir dalam setiap ekson-ekson 12, 21 dan 26 yang dikaji. Dalam kajian ini, 
teknik dHPLC telah berjaya dibangunkan untuk mengesan polimorfisme yang kerap 
berlaku pada gen MDR1 dikalangan pesakit Melayu yang menghidap leukemia di 
institusi ini. Implikasi klinikal bagi penyebaran polimorfisme ini terutamanya dalam 
respon pesakit Melayu yang menghidap leukemia terhadap rawatan haruslah dikaji 
sebagai kajian lanjutan.    
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CHAPTER I 
 
LITERATURE REVIEW 
 
1.1 Research Background 
Leukemia is defined as a neoplasm of the white blood cells (WBC) and its precursor 
which leads to clonal proliferation and accumulation of WBC in bone marrow. Leukemia 
is divided into two categories i.e. myeloid and lymphoid each representing the types of 
cells involved (Denham and Chanarin, 1985). Leukemia can be acute or chronic 
depending on presentation and progression of the clinical manifestations. The incidence 
of leukemia varies with morphological type and is also dependent on age, sex, race and 
locality as will be explained below.  
 
1.1.1 Epidemiology and Etiology of Leukemia 
The incidence of leukemia varies with the morphological type. The frequency of any 
given type of leukemia is also dependent on age, sex, race and locality. In general, acute 
lymphoblastic leukemia (ALL) is a disease of childhood whereas in acute myelogenous 
leukemia (AML) there is a higher incidence with increasing of age (Munker et al., 2000).  
 
In Malaysia, there are 26,089 patients diagnosed with cancers according to the first report 
of the National Cancer Registry (NCR) from 1st January 2002 to 31st December 2002. 
Out of these, there are 11,815 males and 14,274 females. Unregistered cases are 
estimated to be 10,656. In terms of risk, 1 in 6 Malaysians is expected to get cancer in 
his/her lifetime and if taking into account unregistered cases, the risk would be higher i.e. 
 2 
1 in 4 Malaysians. The crude rate for males is 118.9 per 100,000 population and 148.4 
per 100,000 populations in females. Leukemia ranked fourth among cancers in males and 
fifth among cancers in females (Lim et al., 2002). 
 
Etiology of leukemia remains unknown in the majority of patients. However, several risk 
factors have been identified. The association of ionizing radiation in leukemia has been 
firmly established where radiation exposure has been documented by the Atomic Bomb 
Casualty Commission in Hiroshima and Nagasaki (Rowe and Liesveld, 1995). However, 
the role of low-level irradiation and of diagnostic x-rays in the etiology of leukemia 
remains doubtful. Benzene exposure has been strongly associated with development of 
leukemia. Other chemicals such as phenylbutazone, arsenic and chloramphenicol 
exposure have also been related to the development of leukemia (Rowe and Liesveld, 
1995). 
 
Environment has also been recognized as one of the factors contributing to the 
development of leukemia. These include maternal irradiation, in utero irradiation, early 
childhood viral diseases and maternal history of fetal wasting. These factors are often 
difficult to measure and in many instances it is likely that the disease progression are by 
multiple factors rather than a single factor (Rowe and Liesveld, 1995). It is also observed 
that frequency of leukemia is increased in the identical twins of leukemia patient, also in 
those with congenital disorders such as Down syndrome, Bloom syndrome, Fanconi 
syndrome, ataxia-telangiectasia, Kleinfelter syndrome and congenital aneuploidy. Most 
of these congenital disorders are associated with non-random chromosomal aberrations 
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where they might play a role in leukemeogenesis. Relatives of patients with cystic 
fibrosis also may have an increased risk of leukemia (Rowe and Liesveld, 1995). 
 
1.1.1.1 Acute leukemia 
Acute leukemia is a heterogeneous group of malignant disorders characterized by 
uncontrolled clonal proliferation and accumulation of blast cells in the bone marrow, 
blood and other tissues. Acute leukemia is usually rapidly fatal if untreated while chronic 
leukemia is associated with slower progression (Pallister, 1999). Acute leukemia affects 
all age groups from neonates to old age (Provan and Henson, 1998). The accumulation of 
cells in the bone marrow replaces haemopoietic precursor cells and results in bone 
marrow failure. At presentation at least 30% and usually more than 80% of marrow cells 
are blasts. 
 
The disease is divided into two main subgroups, acute myeloid (myeloblastic) leukemia 
(AML) and acute lymphoblastic leukemia (ALL), and further subdivided into various 
subcategories. The French-American-British (FAB) scheme divides AML and ALL into 
various subtypes. There are additional unusual types [see also World Health Organisation 
(WHO)] classification in later part of this dissertation. ALL is the most common 
malignancy of childhood where it accounts for 85% of childhood leukemia. The FAB 
system classifies ALL (Table 1.1) into three subtypes L1, L2 and L3.  
 
ALL is commonest in the age group of 2-10 years with a peak of incidence at 3-4 years. 
The incidence then decreases with increasing age, though there is a secondary rise after 
40 years. ALL affecting B lymphocyte precursors with CD10+ subtype is the most 
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common subtype in children and has an equal sex incidence. On the other hand, there is a 
male preponderance for ALL of T lymphocyte precursor subtype (Provan and Henson, 
1998). 
 
Hematological investigations may reveal a normochromic, normocytic anemia with 
thrombocytopenia in most cases of acute leukemia. The total white cell count may be 
decreased, normal or increased up to 200x109/l or more. Blood film examination typically 
shows variable number of blast cells. The bone marrow is hypercellular with more than 
30% of leukaemic blasts (Munker et al., 2000). 
 
The signs and symptoms of acute leukemia result from the infiltration of the malignant 
blasts into bone marrow and other organs. Signs of anemia are pale skin and mucous 
membranes and easy fatigability. Thrombocytopenia may be a feature as manifested by 
gum bleeding, petechiae, retinal bleeding and easy bruising. Affected children may also 
have bone and joint pains and sometimes a painful enlargement of the spleen.  
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Table 1.1: Table shows the French –American British (FAB) classification of acute 
lymphoblastic leukemia (ALL) into three subtypes. Adapted from (Munker et al., 2000) 
 
 
FAB type Morphological features 
L1 Small homogeneous with scanty cytoplasm, moderate basophilia, 
inconspicuous nuclei. 
L2 Larger, heterogeneous cells, variable cytoplasm, basophilia, 
prominent nucleoli. 
L3 Larger, homogeneous cells with dark basophilic cytoplasm, 
prominent vacuoles, prominent nucleoli. 
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On the other hand, AML is the commonest leukemia (80%) of adulthood where the 
median age at presentation is 60 years old. The incidence of AML is about two to four 
new cases per 100,000 people. AML is rare in children and young adults (Munker et al., 
2000) and forms only a minor fraction of the leukemias in childhood. The sex 
preponderance for AML is the same for both males and females (Provan and Henson, 
1998). 
 However, this is not the case in older patients where males are more susceptible. This is 
most likely due to the fact that myelodysplastic syndromes (MDS) are more common in 
men, and advanced MDS frequently evolves into AML rather than ALL (Provan and 
Henson, 1998). AML is an aggressive hematologic neoplasm that requires urgent 
treatment. The myeloid stem cell is transformed into blasts or myeloblasts which then 
proliferate in the blood and bone marrow and suppresses normal hematopoiesis. 
Myeloblasts proliferate under the influence of myeloid growth factors, some of which are 
produced by the leukemic cells themselves. Consistent with the clonal transformation of 
myeloid stem cells, myeloblasts express cytogenetic abnormalities in 50-70% of cases. 
Cytogenetic studies performed on bone marrow also provide important prognostic 
information.  
According to the FAB classification there are three groups of myeloid malignancies 
whilst WHO classification system groups diseases that show similar characteristics of 
both myeloproliferative and myelodysplastic conditions into a new separate group i.e. 
myeloproliferative/myelodysplastic diseases. This difference in classification is compared 
in Table 1.2.  
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The FAB classification, divides AML into eight sub-types (Table 1.3). The FAB 
subtypes are based on characteristic patterns of cytochemical stains and 
immunophenotype while WHO classification is based on chromosomal aberration 
involved. Table 1.4 compares the different sub-types of AML classification by FAB and 
WHO.  
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Table 1.2 Classification of myeloid malignancies based on French-American-British 
(FAB) and World Health Organization (WHO) 
(http://xenia.sote.hu/depts/pathophysiology/hematology/e/who-classification.html)  
 
FAB WHO 
Chronic myeloproliferative diseases Chronic myeloproliferative diseases 
 Myelodysplastic/myeloproliferative 
diseases 
Myelodysplastic syndromes Myelodysplastic syndromes 
Acute myeloid leukemia Acute myeloid leukemia 
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Table 1.3: French-American-British (FAB) classification of acute myeloid leukemia 
(AML) into eight subtypes. Adapted from (Munker et al., 2000). 
 
FAB types Morphological features 
M0 Undifferentiated  
-lymphoid markers negative, reactive with 
myeloid markers (CD33, CD13), 
ultrastructural peroxidase positive 
 
M1 Myeloid, no maturation 
-poorly differentiated blasts with rare 
azurophilic granules 
 
M2 Myeloid with maturation 
-myeloblasts, promyelocytes, occasionally 
eosinophils and basophils, often Auer rods. 
 
M3 Promyelocytic  
-Two variants: hypergranular (90%) and 
atypical microgranular (<10%) 
 
M4 Myelomonocytic 
-leukemic myeloblasts and monoblasts, 
variant: M4Eo with abnormal eosinophils. 
 
M5 Monoblastic 
-leukemia monoblasts 
 
M6 Erythroleukemia 
-more than 50% abnormal erythropoietic 
cells, >30% myeloblasts of all nonerythroid 
cells 
 
M7 Megakaryoblastic 
-usually associated with myelofibrosis, 
platelet markers present 
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Table 1.4: Shows difference in classification systems of acute myeloid leukemia (AML) 
by French American British (FAB) compared with World Health Organization (WHO) 
and classification systems. 
(http://xenia.sote.hu/depts/pathophysiology/hematology/e/who-classification.html 
 
AML classification 
FAB WHO 
M0: minimally differentiated AML with recurrent cytogenetic 
translocations 
-AML with t(8;21)(q22;q22) 
AML1/CBFalpha/ETO 
-Acute promyelocytic leukemia: 
AML with t(15;17)(q22;q12) and variants 
PML/RARalpha 
-AML with abnormal bone marrow 
eosinophils inv(16)(p13;q22) vagy 
t(16;16)(p13;q22) CBFbeta/MYH1 
-AML with 11q23 MLL abnormalities 
M1: myeloblastic leukemia without 
maturation 
M2: myeloblastic leukemia with 
maturation 
M3: hypergranular promyelocytic leukemia 
M4: myelomonocytic leukemia 
M4Eo: variant, increase in marrow 
eosinophils 
AML with multilineage dysplasia 
With prior MDS 
Without prior MDS 
 
 
M5: monocytic leukemia 
M6: erythroleukemia (DiGuglielmo's 
disease) 
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AML Classification 
FAB WHO 
 
M7: megakaryoblastic leukemia 
AML with myelodysplastic syndrome, 
therapy related 
Alkylating agent related 
Epipodophyllotoxin related 
Other types 
 
AML not otherwise categorized 
AML minimally differentiated 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukemia 
Acute monocytic leukemia 
Acute erythroid leukemia 
Acute megakaryocytic leukemia 
Acute basophilic leukemia 
Acute panmyelosis with myelofibrosis 
 
 
 
 
 
 
 
Table 1.4, continued 
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1.1.1.2 Chronic Leukemia 
Chronic leukemia has a slower progression in terms of clinical manifestation as compared 
to acute leukemia. There are two types of chronic leukemia, chronic myeloid leukemia 
(CML) and chronic lymphocytic leukemia (CLL). CML is a clonal disorder of the 
pluripotent stem cell and is classified as one of the myeloproliferative disorders. The 
disease accounts for around 15% of all leukemias and may occur at any age. 
 
This disease occurs in both sexes with a male: female ratio of 1.4:1 and most frequently 
between the ages of 40 and 60 years. However, it may occur in children and neonates and 
the very old (Pallister, 1999, Provan and Henson, 1998). The diagnosis of CML is rarely 
difficult and is assisted by the characteristic presence of the Philadelphia (Ph) 
chromosome. This results from the reciprocal translocation of chromosomes 9 and 22 as a 
result of which part of the Abelson proto-oncogene (ABL) on chromosome 9 is moved to 
the BCR gene on chromosome 22 and part of BCR gene on chromosome 22 moves to 
ABL gene on chromosome 9. The abnormal chromosome 22 is the Ph chromosome or t 
(9; 22) (q34; q11).  
 
On the other hand, CLL has a peak incidence between 60 and 80 years of age and rarely 
before the age of 40. The male to female ratio is 2:1 (Pallister, 1999, Provan and Henson, 
1998).  It is characterized by a chronic persistent lymphocytosis and subtypes can be 
distinguished by morphology, immuno phenotype and cytogenetics. DNA studies may be 
useful in showing a monoclonal rearrangement of either immunoglobulin or T-cell 
receptor genes. 
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1.2 Chemotherapy Resistance 
The use of chemotherapy in the treatment of leukemia has evolved remarkably during the 
past 30 years, particularly in childhood ALL. However, leukemia remains a difficult 
disease to treat despite recent progress in chemotherapy. The biggest problem limiting the 
effective use of cytotoxic chemotherapy is drug resistance.  Tumors differ in their initial 
chemo sensitivity where some tumors, are very sensitive, resulting in a relatively high 
percentage of responses. Others, such as small-cell lung cancer, are initially sensitive but 
then recur; whereas in others, such as pancreatic cancer, cytotoxic drugs have little 
activity. These differences reflect differences in the biology of the tumor, relating to 
factors such as the growth fraction, the activity of specific drug resistance mechanisms, 
and changes in proteins mediating apoptosis.  
 
A tumor is commonly referred to as resistant if the activity of standard chemotherapy in 
that patient is less than that to be expected in a typical population. Resistance can be 
intrinsic, such that the tumor is resistant to a particular drug or drugs at presentation, or it 
can be acquired, such that resistance develops during treatment. The cellular mechanisms 
mediating drug sensitivity and resistance include target-related changes, changes in drug 
efflux mechanism, drug deactivation, changes in DNA repair and changes in apoptosis. In 
drug efflux process, a number of mechanisms for effluxing xenobiotics exist, their normal 
function being to protect the cell from potentially damaging compounds. Not 
surprisingly, many cytotoxic drugs are effluxed by this mechanism, resulting in decreased 
intracellular drug concentrations. 
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The first of these pumps to be described was P-glycoprotein (P-gp), a member of the 
adenosine triphosphate (ATP)-binding cassette (ABC) super family of transmembrane 
transport proteins. Increased expression of this protein and activity of the pump have 
been described in tumors that are resistant to specific cytotoxic drugs. Moreover, the 
selection of drug-resistant cells by prolonged exposure to specific cytotoxic drugs that are 
P-gp substitutes results in the accumulation of cells with increased P-gp activity that are 
also resistant to  a number of  other structurally, unrelated compounds that are P-gp 
substrates. This phenomenon has been termed multi-drug resistance (MDR) because 
resistance to one P-gp-effluxed drug is associated with resistance to multiple other 
agents. 
 
P-gp is commonly detected in the leukemic cells of patients with AML in who increased 
P-gp, or MDR1 expression, is correlated with increase risk for treatment failure. The 
influence of P-gp and MDR1 on the outcome of patients with ALL is less clear. P-gp 
consists of two homologous halves of six hundred and ten amino acids joined by a 
flexible linker consisting of sixty amino acids (Shen et al., 1986). It is an ATP-dependent 
efflux pump that confers protection to the body from environmental toxins. It transports a 
huge variety of structurally diverse compounds and it was first identified by because it 
was over expressed in human tumor cells.  
Studies have helped to explain the mechanism of action of human P-gp which indicated 
that mutations in membrane-spanning domains or nucleotide binding domains of P-gp are 
involved. According to (Fojo et al., 1985), drug resistance is due to decrease 
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accumulation of these drugs because of an energy-dependent increase in drug efflux 
which results from increased expression of a membrane glycoprotein. 
Recent studies indicate that over expression of P-gp plays a more general anti-apoptotic 
role that extends beyond resistance to chemotherapy. The cells over express P-gp are 
resistant to a wide range of apoptotic inducers. These include serum starvation, fas ligand 
ligation, UV-irradiation and also exposure to tumor necrosis factor (TNF) as well as 
complement-mediated cytotoxic action (Scotto et al., 2003). 
 
P-gp is embedded in lipid membranes, facilitate the import of nutrients into cells or 
releasing the toxic products into the surrounding medium (Higgins, 1992). It is expressed 
in very high levels of the secretory cell type such as adrenal gland and kidney. An 
intermediate level has also been reported in the lung, liver, lower jejunum, colon and 
rectum while low levels are reported in many other tissues where the normal function is 
thought to involve the excretion of toxic metabolites (Schinkel, 1997, Fojo et al., 1986). 
 
This protein is also highly expressed in hematopoietic stem cells, where it is thought to 
protect these cells from toxins. It also has been shown to play a role in the migration of 
dendritic cells (Schinkel et al., 1997). P-gp binds to ATP (Figure 1.1) and use energy to 
drive the transport of various molecules across all cell membranes (Higgins, 1992, Dean 
et al., 2001). This phosphorylation process will cause conformational changes that are 
transmitted to the membrane-spanning domains where finally it transports substrates from 
one side of the membrane to the other. 
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In general, P-gp transports a wide range of substances including ions, sugars, amino 
acids, glycans, peptides, proteins, phospholipids, toxins and drugs. In eukaryotes, most P-
gp move compounds from the cytoplasm to the outside of the cell or into an intracellular 
compartment such as endoplasmic reticulum (ER), mitochondria and peroxisome (Dean 
et al., 2001). 
The P-gp consists of two structurally homologous halves, each with six transmembrane 
domains, one ATP binding site and highly conserved ‘Walker A’ and ‘Walker B’ motif 
(Figure 1.2). These two halves are probably derived from internal gene duplication. It 
was also reported that phosphorylation of P-gp might be essential for drug transport 
(Hrycyna et al., 1996). However, mutation in the major phosphorylation sites within P-gp 
does not affect its transport function. The glycosylated at extracellular sites of P-gp are 
not involved in routing and stability of the protein but it also serve as an antigens for 
monoclonal antibodies recognizing P-gp (Sonneveld, 2000, Schinkel et al., 1993). P-gp  
not only removing an anticancer drug from the inside to the outside of the cell membrane 
using ATP energy, but also prevents the influx of drugs through the cell membrane 
(Juliano and Ling, 1976).  
The classical phenomenon of MDR is seen where levels of P-gp expression was found in 
a large range of cell-lines that were selected through exposure to different cytotoxic 
agents (Kartner et al., 1983). There are two different genes encoding for P-gp in humans, 
MDR1 gene and MDR3 gene, both located on chromosome 7. Despite their homology, 
only MDR1 gene is a drug efflux protein which is related to MDR (Hrycyna et al., 1998). 
Several studies suggested that phosphorylation of P-gp might be essential for drug 
transport (Germann et al., 1996). The glycosylated sites of P-gp at the extracellular site 
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are probably involved in routing and stability of the protein as well as serve also as an 
antigen for monoclonal antibodies in recognizing P-gp (Schinkel et al., 1993).  
Several studies have reported the association between genotype variations with the 
reduction of P-gp expression levels. A single nucleotide change in the coding region of 
MDR1 gene has been found to be associated with the expression level of P-gp. These 
single nucleotide changes are also known as single nucleotide polymorphisms (SNPs).  
MDR represents a form of pleotropic drug resistance that has an adverse prognostic value 
in AML, refractory multiple myeloma and non-Hodgkin’s lymphoma.  It may affect the 
outcome of current chemotherapy protocols (Sonneveld, 2000). Numerous studies have 
investigated the expression of the MDR1 gene products in leukemia, lymphoma and 
myeloma (Hegewisch-Becker and Hossfeld, 1996). Studies in myelogenous leukemia and 
myeloma have so far provided the best evidence for a significant correlation between P-
gp expression and response to chemotherapy (Sonneveld, 2000). 
 
1.2.1 MDR1 Gene also known as Drug Transporter Gene 
Drug transporter gene is the gene that allows drugs to enter cells and in some cases, acts 
to keep them out from membrane cell. Transporter genes may account for discrepancies 
in the way drugs such as antidepressants, anticonvulsants, and chemotherapy agents work 
in different people. The drug-resistant phenotype is due to a membrane alteration which 
reduces the rate of drug permeation (Juliano and Ling, 1976). Surface labeling studies 
reveal that in Chinese hamster, the ovary cell membranes possess a carbohydrate-
containing drug-resistant component. This component is shown to be a cell surface 
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glycoprotein and has a weight of 170 000 Dalton (170 kD) in size. Since this glycoprotein 
is unique to mutant cells displaying altered drug permeability, it has been designated as 
the P-gp. It has been reported to be an important factor in understanding a natural 
resistance of tumors to cytotoxic drugs (Juliano and Ling, 1976).  
1.2.2 Mechanisms of Multi-drug Resistance  
There are two mechanisms of resistance to anticancer drugs, firstly, those that damage 
delivery of anticancer drugs to tumor cells and secondly, those that arise in the cancer cell 
it self due to genetic and epigenetic alterations which can affect drug sensitivity (Jain, 
2001). Cancer cells can become resistant to a single anticancer drug or a class of drugs 
with a similar mechanism of action (Gottesman et al., 2002). It arises either by altering 
the drug’s cellular target or by increasing repair of drug-induced damage, commonly by 
DNA. After selection for resistance to a single drug, cells might also show cross-
resistance to other structurally and mechanistically unrelated drugs.  
 
Cancer cells are genetically heterogeneous because of the mutated phenotype. Tumor 
cells that are exposed to chemotherapeutic agents will be selected for their ability to 
survive and grow in the presence of cytotoxic drugs. Thus, in any population of cancer 
cells that is exposed to chemotherapy, more than one mechanism of multi drug resistance 
can be present. This phenomenon has been called as multi factorial MDR (Gottesman et 
al., 2002).  
 
MDR can also result from activation of coordinately regulated detoxifying systems, such 
as DNA repair and the cytochrome P450 mixed function oxidases. It can be induced after 
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exposure to any drug (Schuetz et al., 1996). Recent evidence indicates that certain orphan 
nuclear receptors might be involved in mediating global response to environmental stress 
(Synold et al., 2001). MDR can also result from defective apoptotic pathways which 
might occur as a result of malignant transformation as in those cancers with mutated or 
non-functional p53 gene (Lowe et al., 1993). Alternatively, cells might acquire changes 
in apoptotic pathways during exposure to chemotherapy, such as changes in cell-cycle 
machinery, leading to an activated checkpoints which prevents initiation of apoptosis 
(Lowe et al., 1993). 
1.2.2.1 ABCB1 Gene Family 
Classical MDR results from expression of ATP-dependent efflux pumps with broad drug 
specificity (Gottesman et al., 2002). These pumps belong to a family of ATP-binding 
cassette (ABC) transporters which share sequence and structural homology. So far, 
fourty-eight human ABC genes have been identified and divided into seven distinct 
subfamilies (ABCA, ABCB, ABCC, ABCD,… and ABCG) on the basis of their 
sequence homology and domain organization (Dean et al., 2001). Drugs that are affected 
by classical MDR include vinca alkaloids (vinblastine, vincristine), the anthracyclines 
(doxorubicin, daunorubicin), the RNA transcription inhibitor actinomycin-D and the 
microtubule-stabilizing drug paclitaxel (Ambudkar et al., 1999).  
The ABCB1 gene maps to chromosome 7q21.1 and is the best characterized ABC drug 
pump (Figure 1.3). Formerly known as MDR1 gene or P-gp, ABCB1 gene was the first 
human ABC transporter cloned and characterized through its ability to confer a MDR 
phenotype to cancer cells that had developed resistance to chemotherapy drugs (Roninson 
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et al., 1986, Juliano and Ling, 1976). The gene is thought to play an important role in 
removing toxic metabolites from cells. It also expressed in cells at the blood brain barrier 
and may play a role in transporting compounds into the brain that cannot be delivered by 
diffusion (Hoffmeyer et al., 2000).  
P-gp belongs to the ABC transporter subfamily B1 and is encoded by the ABCB1 gene 
(Ueda et al., 1987). ABCB1 gene is found to be over expressed in all MDR human cell 
lines. It consists of 28 exons and 26 introns and encodes a transporter P-gp.  
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Figure 1.1: The figure shows the process of phosphorylation of P-gp. This 
process is essential for transport activity of the drugs into the membrane cell. This 
figure cited from http://images.search.yahoo.com/search/images?p=+p-
glycoprotein&ei=UTF 8&fl=0&imgsz=all&fr=FP-tab- img-t&b=41.  
 
 
 
 
 
 
 
 
 
 
Extracellular site 
Intracellular site 
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Figure 1.2: Schematic representation of P-gp. It contains two ATP-binding sites, 
phosphorylation sites and glycosylation sites as well as comprises of 1280 amino acid 
sequences (Sonneveld, 2000). 
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Figure 1.3: The MDR1 gene is located at the q-arm of chromosome 7 at position 
21.1. The ideogram shows the location of MDR1 gene on the chromosome. 
(http://www.ncbi.nlm.nih.gov/mapview/maps.) The OMIM reference code: # 
171650. 
 
 
 
 
 
 
MDR1 gene located at 
7q21.1 on chromosome 7. 
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1.2.3 Expression of P-gp in Normal Cells. 
P-gp is differentially expressed in normal tissues as a consequence of differentiation 
triggers and response to environmental challenges. High levels of P-gp expression are 
found in the kidney and adrenal glands. Expression of P-gp is also high in the colon and 
in the endothelial cells of the blood-brain and blood-testes barrier, where it plays a role in 
the pharmacokinetic and bio-distribution of xenobiotics. Furthermore, environmental 
factors such as heat shock, cytokines, hormones, differentiation agents, 
chemotherapeutics, dietary products, UV and X-irradiation, receptor agonists, oncogenes 
and tumor suppressor genes can influence the levels of specific P-gp isoforms in different 
systems. Therefore, P-gp expression is controlled by the highly complex interplay of a 
variety of factors that are involved in multiple regulatory pathways (Schwab et al., 2003). 
P-gp is involved in limiting absorption of xenobiotics from the gut lumen, in protection 
of sensitive tissues (brain, fetus, testes) and in biliary and urinary excretion of its 
substrates (Schwab et al., 2003). P-pg has an important role in regulating central nervous 
system permeability. The brain is protected against blood-borne toxins by the blood-brain 
barrier (BBB) and the blood-cerebrospinal-fluid (CSF) barrier. P-gp is located on the 
luminal surface, preventing the penetration of cytotoxins across the endothelium (Rao et 
al., 1999). 
P-gp plays an important role to protect the testicular tissues and transports toxins into the 
capillary lumen in the testes (Cordon-Cardo et al., 1990). In the placenta, P-gp is 
localized on the apical syncytiotrophoblast and involved in developing of fetus by 
protecting from toxic cationic xenobiotic. In the liver, gastrointestinal tract and kidney, P-
gp is responsible to excrete toxin thus protecting the entire organisms (Schinkel, 1997).  
